Aquestive Therapeutics Statistics
Want to see AQST full AI Analyst Report?
Aquestive Therapeutics (AQST) Stock Statistics & Valuation Metrics
Total Valuation
Aquestive Therapeutics has a market cap or net worth of $442.42M. The enterprise value is $640.76M.
- Market Cap
- $442.42M
- Enterprise Value
- $640.76M
Share Statistics
Aquestive Therapeutics has 125,687,706 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 125,687,706
- Owned by Insiders
- 2.11%
- Owned by Institutions
- 29.34%
Financial Efficiency
Aquestive Therapeutics’s return on equity (ROE) is 2.49 and return on invested capital (ROIC) is -55.97%.
- Return on Equity (ROE)
- 2.49
- Return on Assets (ROA)
- -0.52
- Return on Invested Capital (ROIC)
- -55.97%
- Return on Capital Employed (ROCE)
- -0.62
- Revenue Per Employee
- 303.03K
- Profits Per Employee
- -569.96K
- Employee Count
- 147
- Asset Turnover
- 0.28
- Inventory Turnover
- 2.78
Valuation Ratios
The current PE Ratio of Aquestive Therapeutics is -5.50. Aquestive Therapeutics’s PEG ratio is -1.32.
- PE Ratio
- -5.50
- PS Ratio
- 9.05
- PB Ratio
- 0.00
- Price to FCF
- -10.86
- Price to Operating Cash Flow
- -11.11
- PEG Ratio
- -1.32
Income Statement
In the last 12 months, Aquestive Therapeutics had revenue of 44.55M and earned -83.78M in profits. Earnings per share was -0.76.
- Revenue
- 44.55M
- Gross Profit
- 27.39M
- Operating Income
- -69.65M
- Pretax Income
- -83.78M
- Net Income
- -83.78M
- EBITDA
- -66.14M
- Earnings Per Share (EPS)
- -0.76
Cash Flow
In the last 12 months, operating cash flow was -39.76M and capital expenditures -933,000, giving a free cash flow of -40.70M billion.
- Operating Cash Flow
- -39.76M
- Free Cash Flow
- -40.70M
- Free Cash Flow per Share
- -0.32
Dividends & Yields
Aquestive Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.04%
- Earnings Yield
- -17.61%
Stock Price Statistics
- Beta
- 0.97
- 52-Week Price Change
- -36.92%
- 50-Day Moving Average
- 4.54
- 200-Day Moving Average
- 4.24
- Relative Strength Index (RSI)
- 31.27
- Average Volume (3m)
- 2.71M
Important Dates
Aquestive Therapeutics upcoming earnings date is Mar 09, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 03, 2026
- Next Earnings Date
- Mar 09, 2027
- Ex-Dividend Date
- ―
Financial Position
Aquestive Therapeutics as a current ratio of 3.14, with Debt / Equity ratio of -390.48%
- Current Ratio
- 3.14
- Quick Ratio
- 3.01
- Debt to Market Cap
- 0.16
- Net Debt to EBITDA
- -0.16
- Interest Coverage Ratio
- -4.07
Taxes
In the past 12 months, Aquestive Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Aquestive Therapeutics EV to EBITDA ratio is -5.67, with an EV/FCF ratio of -9.04.
- EV to Sales
- 7.53
- EV to EBITDA
- -5.67
- EV to Free Cash Flow
- -9.04
- EV to Operating Cash Flow
- -9.25
Balance Sheet
Aquestive Therapeutics has $90.35M in cash and marketable securities with $8.10M in debt, giving a net cash position of $82.25M billion.
- Cash & Marketable Securities
- $90.35M
- Total Debt
- $8.10M
- Net Cash
- $82.25M
- Net Cash Per Share
- $0.65
- Tangible Book Value Per Share
- -$0.56
Margins
Gross margin is 65.34%, with operating margin of -114.12%, and net profit margin of -162.33%.
- Gross Margin
- 65.34%
- Operating Margin
- -114.12%
- Pretax Margin
- -162.33%
- Net Profit Margin
- -162.33%
- EBITDA Margin
- -132.73%
- EBIT Margin
- -133.51%
Analyst Forecast
The average price target for Aquestive Therapeutics is $9.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $9.20
- Price Target Upside
- 161.36% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- 12.54%
- EPS Growth Forecast
- 8.82%
Scores
- Smart Score
- 8
- AI Score
- 47
